In the Phase 1 ANTLER trial, vispa-cel demonstrated an 82% overall response rate and a 67% complete response rate in patients with second-line large B cell lymphoma.

Health news, debates, and claims covering public health, mental health, nutrition, medical care, and health policy.

Cancer treatment, oncology drug access, hematologic malignancies, and cancer drug policy.

Blood cancers and hematologic malignancies including leukemia, lymphoma, and related disorders.